Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com -- Maia Biotechnology Inc (NYSE:MAIA) stock surged 10% after the clinical-stage biopharmaceutical company announced the publication of promising preclinical data from its second-generation ateganosine prodrugs platform in the peer-reviewed journal Nucleic Acids Research.
The study, titled "Novel Telomere-Targeting Dual-Pharmacophore Dinucleotide Prodrugs for Anticancer Therapy," details the company’s lead ateganosine-derived second-generation prodrugs as potential new molecules for enhancing cancer treatment and overcoming drug resistance.
According to the publication, MAIA designed and synthesized divalent dinucleotide prodrugs comprised of two nucleosides. The lead THIO-containing compounds demonstrated strong anticancer efficacy in vivo and induced robust host immune-memory responses.
The company’s Chairman and CEO Vlad Vitoc noted that the sequential combination of their lead compounds MAIA-2022-12 or MAIA-2021-20 with an immune checkpoint inhibitor "demonstrated a significantly lower 50% inhibitory concentration with superior anticancer efficacy compared with the corresponding monotherapies."
MAIA nominated one lead new molecular entity candidate (MAIA-2021-20) and one back-up candidate (MAIA-2022-12) in January 2023 for advancement into preclinical GLP-toxicity studies. The company is now working to advance at least one of these candidates into human clinical trials upon completion of required evaluations.
The manuscript with the data was published on June 26, 2025, in Volume 53, Issue 12 of the Nucleic Acids Research journal.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.